COVID-19 Vaccine Innovators Hit the U.S. House FloorJuly 21, 2020
Ahead of the hearing, let’s look at what we know about those efforts and preparations already.
Right now, there are two vaccine candidates in Phase Three clinical trials – one is the result of a partnership between AstraZeneca and the University of Oxford. The University of Oxford recently embarked on a trial with 5,000 volunteers in Brazil – a coronavirus hotspot – to test the efficacy of their vaccine candidate. Preliminary results are expected as soon as October.
Just yesterday, Moderna published data in the New England Journal of Medicine which showed that their vaccine produced an immune response in a Phase One study. The company will begin a Phase Three trial testing the vaccine in 30,000 participants on July 27.
Other companies are tracking closely behind.
Merck plans to utilize its long-standing leadership in vaccine development to address COVID-19. CEO Ken Frazier recently noted that “In the last quarter-century, there have only been seven truly new vaccines introduced globally at the clinical practice… Merck has four.” The company soon hopes to add a fifth with a COVID-19 vaccine. Merck is currently investigating whether its previously approved Ebola and Measles vaccines can be re-engineered to combat COVID-19.
On Monday, Pfizer and its German partner BioNTech, received fast track designation from the FDA for two of its four vaccine candidates, which will help speed up regulatory approval should one of them prove to be effective during their Phase 1/2 clinical trial, happening now.
And Johnson & Johnson recently selected a leading vaccine candidate and plans to begin a Phase 1/2a clinical trial in the coming weeks.
With the full innovative capacity of these companies dedicated to identifying an effective coronavirus vaccine, we remain hopeful that we will soon have an immunization to help place us on the return to a new normal in the wake of COVID-19.
This update was provided by the U.S. Chamber of Commerce’s Global Innovation Policy Center,.